Clinical trial
Phase 4 Study of Dolutegravir (DTG) in Russian Federation
NCT03314064
Study timeline
Study start (actual)2016-12-08Date precision: day
Registry last updated2019-02-04
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Infection, Human Immunodeficiency Virusunresolved
HIV Infectionsunresolved
Interventions
Dolutegravir 50 mgDRUG · verified · RxNorm: dolutegravir 50 MG
Sponsors & collaborators
ViiV Healthcarelead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03314064 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.